Compositions comprising bacterial strains

Patent metadata

Field	Value
Publication number	US-11376284-B2
Application number	US-201916692667-A
Country	US
Kind code	B2
Filing date	Nov 22, 2019
Priority date	May 22, 2017
Publication date	Jul 5, 2022
Grant date	Jul 5, 2022

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing central nervous system disorders and conditions.

First claim

The invention claimed is:

1. A method of treating repetitive, stereotyped, compulsive, or anxious behavior caused by a neurodevelopmental disorder or a neuropsychiatric condition in a subject in need thereof, comprising administering to said subject a pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Blautia comprising a 16S rRNA gene sequence of SEQ ID NO:2 or SEQ ID NO:4, wherein said administering is effective to treat said behavior in said subject.

2. The method of claim 1 , wherein said subject has said neurodevelopmental disorder, and wherein said neurodevelopmental disorder is an autism spectrum disorder (ASD) or a child developmental disorder.

3. The method of claim 2 , wherein said subject has said ASD, and wherein said ASD is autism or Asperger Syndrome.

4. The method of claim 1 , wherein said subject has said neuropsychiatric condition, and wherein said neuropsychiatric condition is selected from the group consisting of obsessive compulsive disorder (OCD), major depressive disorder, seasonal affective disorder, an anxiety disorder, chronic fatigue syndrome, post-traumatic stress disorder, a schizophrenia spectrum disorder, bipolar disorder, psychosis, and mood disorder.

5. The method of claim 4 , wherein said subject has said schizophrenia spectrum disorder, and wherein said schizophrenia spectrum disorder is schizophrenia.

6. The method of claim 4 , wherein said subject has said anxiety disorder, and wherein said anxiety disorder is selected from the group consisting of generalized anxiety disorder (GAD), specific phobia, social anxiety disorder, separation anxiety disorder, agoraphobia, panic disorder, and selective mutism.

7. The method of claim 1 , wherein said bacteria strain is live and capable of at least partially colonizing an intestine of said subject.

8. The method of claim 1 , wherein said pharmaceutical composition is formulated for delivery to an intestine of said subject.

9. The method of claim 1 , wherein said bacteria strain is of the species Blautia stercoris or Blautia wexlerae.

10. The method of claim 1 , wherein said bacteria strain is the bacteria strain deposited under accession number NCIMB 42381 or the bacteria strain deposited under accession number NCIMB 42486.

11. The method of claim 1 , wherein said subject is human.

12. A method of treating behaviors in a subject suffering from a neurocognitive disorder, comprising administering to said subject a pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Blautia comprising a 16S rRNA gene sequence of SEQ ID NO:2 or SEQ ID NO:4, wherein said administering is effective to treat said behaviors in said subject.

13. The method of claim 12 , wherein said neurocognitive disorder is selected from the group consisting of Alzheimer's disease, vascular dementias, Lewy body disease, frontotemporal dementia, Parkinson's disease, Creutzfeldt-Jakob disease, Huntington's disease, and Wernicke-Korsakoff syndrome.

Assignees

• 4D Pharma Res Ltd

Inventors

• Savignac Helene
• MULDER Imke Elisabeth
• Stevenson Alexander James
• Dinan Ted
• Cryan John

Classifications

• A61P25/22

  Anxiolytics · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61K9/48

  Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61K9/0031

  Rectum, anus · CPC title